Cardiol Therapeutics (NASDAQ:CRDL) is a clinical-stage biotechnology company focused on developing immunomodulatory therapies for serious cardiovascular diseases. Headquartered in Toronto, Canada, the company leverages proprietary formulations of cannabidiol (CBD) to target inflammatory pathways implicated in acute and chronic cardiac conditions. Since its founding, Cardiol has maintained a research-driven approach, partnering with leading academic institutions and contract research organizations to advance its pipeline from preclinical studies through to late-stage clinical programs.
The company’s lead product candidate, CardiolRx, is an intravenously administered formulation of synthetic CBD designed to mitigate the damage caused by acute myocarditis, a potentially life-threatening inflammation of the heart muscle. Preclinical models have demonstrated that CardiolRx can attenuate inflammatory cell infiltration and reduce cardiac fibrosis, supporting the rationale for its ongoing Phase II clinical trial. In addition to myocarditis, Cardiol is exploring the therapeutic potential of its CBD platform in other cardiovascular settings, including acute myocardial infarction and chronic heart failure.
Cardiol’s clinical development program spans North America and Europe, reflecting a strategic focus on regions with strong regulatory pathways for novel cardiac therapies. The company has initiated collaborations with leading research hospitals in the United States and Canada to enroll patients in its myocarditis study, while simultaneously engaging with regulatory agencies to align on trial design and endpoints. Manufacturing of CardiolRx is conducted under current Good Manufacturing Practices (cGMP), ensuring supply chain robustness for both clinical and future commercial demands.
Led by President and CEO Thomas W. Shea, Cardiol benefits from an experienced management team with deep expertise in cardiovascular drug development, regulatory affairs and commercial strategy. The board of directors includes recognized thought leaders in cardiology and biotechnology, providing governance and oversight as the company advances its pipeline. With its novel CBD-based approach, Cardiol Therapeutics aims to address significant unmet needs in cardiovascular care by offering targeted anti-inflammatory treatments to improve patient outcomes.
